(Q37947095)

25 August 2017

title

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs (English)

1 reference

25 August 2017

1 reference

5

Christoph U Correll

1 reference

25 August 2017

Marc De Hert

1

1 reference

25 August 2017

Johan Detraux

series ordinal

2

1 reference

25 August 2017

Ruud van Winkel

series ordinal

3

1 reference

25 August 2017

Weiping Yu

series ordinal

4

1 reference

25 August 2017

publication date

18 October 2011

1 reference

Nature Reviews Endocrinology

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

114-126

1 reference

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

National trends in psychotropic medication polypharmacy in office-based psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Past and present progress in the pharmacologic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotic drugs and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic screening in children receiving antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Weight effects associated with antipsychotics: a comprehensive database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Weight gain in antipsychotic-naive patients: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Adverse events in children and adolescents treated with antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Treatment with antipsychotics and the risk of diabetes in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

MTHFR and risk of metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Mechanisms and genetics of antipsychotic-associated weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotics and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Sudden deaths in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Thioridazine and sudden unexplained death in psychiatric in-patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

A UK audit of screening for the metabolic side effects of antipsychotics in community patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic syndrome associated with schizophrenia and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Inequitable access for mentally ill patients to some medically necessary procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiovascular risk assessment and management in mental health clients: whose role is it anyway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiovascular aspects of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Schizophrenia and increased risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

The effects of undertreated chronic medical illnesses in patients with severe mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Use of waist circumference to predict insulin resistance: retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Waist circumference measurement in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

QT interval duration and dispersion in children and adolescents treated with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Management of antipsychotic-related weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Switching among antipsychotics in everyday clinical practice: focus on ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

The association between weight change and symptom reduction in the CATIE schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Metabolic syndrome in people with schizophrenia: a review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

International Diabetes Federation: a consensus on Type 2 diabetes prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Antipsychotics and diabetes: an age-related association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.156

Treatment decisions in major mental illness: weighing the outcomes.

31 March 2020

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

1 reference

12 December 2020

Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.

1 reference

12 December 2020

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis

1 reference

12 December 2020

How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications

1 reference

12 December 2020

Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care.

1 reference

12 December 2020

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

12 December 2020

Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia

1 reference

12 December 2020

Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Prediabetes in patients treated with antipsychotic drugs.

1 reference

12 December 2020

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.156

1 reference

25 August 2017

1 reference